Direxion Daily S&P Biotech Bear 3X ETF

LABD

Market cap $71M

LABD Hedge Fund Activity: Q1 2026 in Review

17 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q1 2026, worth a combined $11.3M — down 23% from $14.6M a quarter earlier.

Fund positioning in LABD was balanced in Q1 2026: 6 funds opened new positions, 6 closed out, 5 added to existing stakes and 6 trimmed.

The largest buyer was Capstone Capital Management, opening a new position worth an estimated $1.9M. The largest seller was Jump Financial, exiting entirely with an estimated $2.97M sold.

• 17 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q1 2026, unchanged from Q4 2025.
• Funds reported $11.3M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q1 2026, down 23% quarter-over-quarter.
• 6 funds opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q1 2026 and 6 closed out, a net change of 0 holders.
• The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q1 2026 was Capstone Capital Management, an estimated $1.9M added.
• The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q1 2026 was Jump Financial, an estimated $2.97M sold.

Based on aggregated 13F filings for Q1 2026.